All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference Listing
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Gemtuzumab Ozogamicin Recommended for Approval by ODAC for Newly Diagnosed AML

Jul 12, 2017
Jason Harris

In a 6-1 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted in favor of approving gemtuzumab ozogamicin in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia.

David Harrington, PhD

David Harrington, PhD

In a 6-1 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted in favor of approving gemtuzumab ozogamicin (Mylotarg) in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).

The committee agreed that the anti-CD33 antibody conjugate administered in a fractionated low-dose schedule was safe for use in this patient population. The full FDA is scheduled to issue a final ruling later this year.

Pfizer submitted results from ALFA-0701, the randomized phase III trial comparing daunorubicin and cytarabine with (n = 139) or without gemtuzumab (n = 139) for the treatment of patients 50 to 70 years old with newly-diagnosed AML to support this Biologics License Application (BLA).

Gemtuzumab 3 mg/m2was administered on days 1, 4, and 7 during induction and day 1 of each of the two consolidation chemotherapy courses. The primary endpoint was event-free survival (EFS) with a secondary endpoint of overall survival (OS).

Gemtuzumab was associated with a statistically significant improvement in EFS of 7.8 months (hazard ratio [HR], 0.56; 95% CI 0.42, 0.76;P< 0.001). However, the drug was not associated with a significant improvement in OS (HR 0.81; 95% CI, 0.60-1.09;P= 0.16). The FDA usually uses OS as the endpoint to confirm clinical benefit for the treatment of AML, so the committee had to determine if improved EFS outcomes were enough to justify approval.

&ldquo;I&rsquo;m convinced that EFS is a meaningful clinical endpoint even if not predictive or highly correlated with survival,&rdquo; David Harrington, PhD, professor of biostatistics at Dana-Farber Cancer Institute, said in explaining his vote in support of gemtuzumab. He added that though there are clear safety risks with the drug, they appear to be in-line with other options. &ldquo;It doesn&rsquo;t seem substantially more dangerous than other treatments.&rdquo;

There was no significant difference in 30-day mortality between the 2 groups, but patients treated with gemtuzumab had a higher rate of grade &ge;3 hemorrhage (23% vs 7%) and a prolonged time to recovery of platelets. A fifth of patients in the gemtuzumab arm had delay in recovery of at least 45 days.

In a trial-level analysis of 33 randomized studies in untreated patients with de novo AML, the trial-level weighted R2was only 0.46 (95% CI 0.23, 0.70). An R2close to 1 indicates strong trial-level surrogacy. Furthermore, in the subgroup of 5 randomized studies for which patient-level data were available, the weighted R2through a copula model was 0.45 (95% CI 0.00-1.00) and 0.61 (95% CI 0.20-1.00) without application of a copula model. ODAC staff found that EFS was &ldquo;clearly not predictive of OS&rdquo; in the patient-level analysis, particularly for patients who did not achieve complete response.

Patients in the gemtuzumab arm were 7 times more likely to experience any adverse events (AE) compared with the control arm (27% vs 4%), and gemtuzumab patients were more than 4 times more likely to discontinue treatment due to AEs (31% vs 7%). No patients in the control arm developed thrombocytopenia versus 15% in the gemtuzumab arm. Patients in the experimental arm were also more likely to experience hepatobiliary disorders (6% vs <1%).

Of the 35 patients who discontinued gemtuzumab due to an AE, 14 patients continued treatment with daunorubicin and cytarabine. Twelve discontinued gemtuzumab due to thrombocytopenia, and 2 discontinued due to grade 2/3 hepatotoxicity.

Overall, 8 patients developed veno-occlusive disease. Seven patients developed veno-occlusive disease without hematopoietic stem cell transplantation, and 1 developed the condition 25 days after transplantation.

Six patients (4.6%) who developed veno-occlusive disease were in the gemtuzumab arm; 3 of those cases were fatal and 2 were found to be treatment-related. The remaining 2 patients with veno-occlusive disease were initially assigned to daunorubicin and cytarabine, but received gemtuzumab treatment after relapse and subsequently developed veno-occlusive disease.

The FDA awarded Accelerated Approval to gemtuzumab in 2000 for the treatment of patients 60 years or older with CD33-positive AML in first relapse who were not considered candidates for cytotoxic chemotherapy. Wyeth, now Pfizer, voluntarily pulled the drug from the market in 2010 after results from the SWOG-S0106 trial showed that gemtuzumab did not improve rate of complete response, disease-free survival (DFS) or OS compared with daunorubicin and cytarabine.

Results from subsequent trials suggested that a lower dose—the previous regimen was 2 doses of 9 mg/m2

Related Videos
Abdulraheem Yacoub, MD, an expert on myelofibrosis
Abdulraheem Yacoub, MD, an expert on myelofibrosis
Abdulraheem Yacoub, MD, an expert on myelofibrosis
Abdulraheem Yacoub, MD, an expert on myelofibrosis
Abdulraheem Yacoub, MD, an expert on myelofibrosis
Abdulraheem Yacoub, MD, an expert on myelofibrosis
Related Content

FDA Lifts Partial Clinical Hold on Study of FHD-286 in R/R AML, MDS

June 8th 2023

ASCO Presentation Provides Real World Evidence of Brexu-cel’s Efficacy in R/R B-ALL

June 2nd 2023

Obe-cel Induces 76% CR/CRi Rate With Compelling MRD Negativity in R/R B-ALL

June 2nd 2023

Imetelstat Displays Significant Efficacy in R/R Myelodysplastic Syndrome

June 2nd 2023

Luspatercept Increases Probability of Transfusion Independence in Lower-Risk MDS

May 26th 2023

Voruciclib +/- Venetoclax Yeilds Promising Efficacy in AML or B-Cell Malignancies

May 25th 2023

FDA Lifts Partial Clinical Hold on Study of FHD-286 in R/R AML, MDS

June 8th 2023

ASCO Presentation Provides Real World Evidence of Brexu-cel’s Efficacy in R/R B-ALL

June 2nd 2023

Obe-cel Induces 76% CR/CRi Rate With Compelling MRD Negativity in R/R B-ALL

June 2nd 2023

Imetelstat Displays Significant Efficacy in R/R Myelodysplastic Syndrome

June 2nd 2023

Luspatercept Increases Probability of Transfusion Independence in Lower-Risk MDS

May 26th 2023

Voruciclib +/- Venetoclax Yeilds Promising Efficacy in AML or B-Cell Malignancies

May 25th 2023

FDA Lifts Partial Clinical Hold on Study of FHD-286 in R/R AML, MDS

June 8th 2023

ASCO Presentation Provides Real World Evidence of Brexu-cel’s Efficacy in R/R B-ALL

June 2nd 2023

Obe-cel Induces 76% CR/CRi Rate With Compelling MRD Negativity in R/R B-ALL

June 2nd 2023

Imetelstat Displays Significant Efficacy in R/R Myelodysplastic Syndrome

June 2nd 2023

Luspatercept Increases Probability of Transfusion Independence in Lower-Risk MDS

May 26th 2023

Voruciclib +/- Venetoclax Yeilds Promising Efficacy in AML or B-Cell Malignancies

May 25th 2023
Related Content

FDA Lifts Partial Clinical Hold on Study of FHD-286 in R/R AML, MDS

FDA Lifts Partial Clinical Hold on Study of FHD-286 in R/R AML, MDS

June 8th 2023
Article

Now that the FDA has lifted the partial clinical hold on the phase 1 study of FHD-286 in patients with relapsed/refractory acute myelogenous leukemia and myelodysplastic syndrome, there are plans to initiate a trial to further assess the agent with decitabine or cytarabine.

Read More


ASCO Presentation Provides Real World Evidence of Brexu-cel’s Efficacy in R/R B-ALL

ASCO Presentation Provides Real World Evidence of Brexu-cel’s Efficacy in R/R B-ALL

June 2nd 2023
Article

In a real-world population of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, modest efficacy was demonstrated with brexucabtagene autoleucel.

Read More


Obe-cel Induces 76% CR/CRi Rate With Compelling MRD Negativity in R/R B-ALL

Obe-cel Induces 76% CR/CRi Rate With Compelling MRD Negativity in R/R B-ALL

June 2nd 2023
Article

Phase 2 FELIX study results show 21.3% of the 94 patients infused with obecatagene autoleucel achieved a complete response or complete response with incomplete count recovery.

Read More


Imetelstat Displays Significant Efficacy in R/R Myelodysplastic Syndrome

Imetelstat Displays Significant Efficacy in R/R Myelodysplastic Syndrome

June 2nd 2023
Article

In a phase 3 study, imetelstat has shown prolonged transfusion independence and hemoglobin increase in the relapsed or refractory myelodysplastic syndrome population.

Read More


Luspatercept Increases Probability of Transfusion Independence in Lower-Risk MDS

Luspatercept Increases Probability of Transfusion Independence in Lower-Risk MDS

May 26th 2023
Article

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

Read More


Voruciclib +/- Venetoclax Yeilds Promising Efficacy in AML or B-Cell Malignancies

Voruciclib +/- Venetoclax Yeilds Promising Efficacy in AML or B-Cell Malignancies

May 25th 2023
Article

When used as a monotherapy or in combination with venetoclax, voruciclib was generally well tolerated and showed an encouraging preliminary efficacy signal in patients with acute myeloid leukemia or B-cell malignancies.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.